Format
Sort by

Send to

Choose Destination

Search results

Items: 5

1.

Amyloid β peptides are differentially vulnerable to preanalytical surface exposure, an effect incompletely mitigated by the use of ratios.

Toombs J, Foiani MS, Wellington H, Paterson RW, Arber C, Heslegrave A, Lunn MP, Schott JM, Wray S, Zetterberg H.

Alzheimers Dement (Amst). 2018 Mar 22;10:311-321. doi: 10.1016/j.dadm.2018.02.005. eCollection 2018.

2.

Molecular biomarkers of Alzheimer's disease: progress and prospects.

Lashley T, Schott JM, Weston P, Murray CE, Wellington H, Keshavan A, Foti SC, Foiani M, Toombs J, Rohrer JD, Heslegrave A, Zetterberg H.

Dis Model Mech. 2018 May 8;11(5). pii: dmm031781. doi: 10.1242/dmm.031781. Review.

3.

CSF neurogranin or tau distinguish typical and atypical Alzheimer disease.

Wellington H, Paterson RW, Suárez-González A, Poole T, Frost C, Sjöbom U, Slattery CF, Magdalinou NK, Lehmann M, Portelius E, Fox NC, Blennow K, Zetterberg H, Schott JM.

Ann Clin Transl Neurol. 2018 Jan 11;5(2):162-171. doi: 10.1002/acn3.518. eCollection 2018 Feb.

4.

Amyloid precursor protein expression and processing are differentially regulated during cortical neuron differentiation.

Bergström P, Agholme L, Nazir FH, Satir TM, Toombs J, Wellington H, Strandberg J, Bontell TO, Kvartsberg H, Holmström M, Boreström C, Simonsson S, Kunath T, Lindahl A, Blennow K, Hanse E, Portelius E, Wray S, Zetterberg H.

Sci Rep. 2016 Jul 7;6:29200. doi: 10.1038/srep29200.

5.

Increased CSF neurogranin concentration is specific to Alzheimer disease.

Wellington H, Paterson RW, Portelius E, Törnqvist U, Magdalinou N, Fox NC, Blennow K, Schott JM, Zetterberg H.

Neurology. 2016 Mar 1;86(9):829-35. doi: 10.1212/WNL.0000000000002423. Epub 2016 Jan 29.

Supplemental Content

Loading ...
Support Center